Trial Profile
A Placebo-Controlled, Dose-Escalation Study in HIV-1 Infected Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of DPC 817.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2009
Price :
$35
*
At a glance
- Drugs Dexelvucitabine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pharmasset
- 23 Oct 2009 New trial record